Related Experiment Videos
Surveillance for hepatocellular carcinoma
1University of Toronto and University Health Network, Toronto, Ontario, Canada.
Seminars in Oncology
|October 31, 2001
Summary
Surveillance for hepatocellular carcinoma (HCC) in high-risk patients, like cirrhosis or hepatitis B carriers, is common but lacks definitive proof of reduced mortality. Ultrasound is preferred over Alphafetoprotein (AFP) for screening.
Area of Science:
- Hepatology
- Oncology
- Medical Screening
Background:
- Surveillance for hepatocellular carcinoma (HCC) in patients with risk factors is debated.
- Appropriate populations include cirrhosis patients and hepatitis B (HBV) carriers.
- Risk stratification within these groups is possible.
Purpose of the Study:
- To evaluate the evidence and practice of HCC surveillance.
- To assess the effectiveness of screening methods like ultrasound and Alphafetoprotein (AFP).
- To determine if HCC surveillance reduces disease-specific mortality.
Main Methods:
- Review of existing literature and modeling studies on HCC surveillance.
- Assessment of ultrasound and AFP as screening tools.
- Evaluation against general cancer surveillance criteria.
Main Results:
- No randomized controlled trials confirm reduced HCC mortality with surveillance.
- Ultrasound is considered the most appropriate test, but optimal intervals are undefined.
- AFP lacks sensitivity and specificity for HCC surveillance.
Conclusions:
- HCC surveillance is common practice despite limited evidence of mortality reduction.
- Screening may identify small HCCs for therapeutic trials.
- More effective treatments are needed to improve surveillance outcomes.